Tatsuya Yoshida
Chuo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 336 publications
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: June 10, 2026
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 05, 2026
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 08, 2026
Updated consensus terminology and definitions in chest electrical impedance tomography.
Journal: Physiological measurement
Published: April 24, 2026
Impact of travel costs on disparities in precision oncology clinical trials.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Journal: Expert review of anticancer therapy
Published: February 05, 2026
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC).
Journal: Future oncology (London, England)
Published: February 05, 2026
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2026
A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
Journal: Investigational new drugs
Published: January 15, 2026
Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance.
Journal: Respiratory investigation
Published: December 08, 2025
Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti-Programmed Cell Death Protein 1 in SCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 03, 2025
Last Updated: 09/26/2026